

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 7 contd.






Figure 7 contd.

D**Training cohort****No. at Risk**

Good prognosis	30	25	21	8	4	1	0
Poor prognosis	27	12	7	4	0	0	0

E**Validation cohort****No. at Risk**


Good prognosis	53	42	30	22	15	5	4	2	0	0
Poor prognosis	45	26	14	9	7	4	3	3	2	0

10/41

Figure 8

A


**Stage I:
14-immune gene signature**

**No. at Risk**

Good prognosis	36	34	25	13	8	3	1	1	0
Poor prognosis	19	14	7	4	2	1	0	0	0


B

**Stage I:
Grade**


**No. at Risk**

Grade 1+2	37	34	23	12	5	1	0	0	0
Grade 3+4	13	9	6	2	2	1	1	1	0

Figure 8 contd.

C**No. at Risk**

Good prognosis	24	19	16	10	6	1	1	0
Poor prognosis	22	8	2	0	0	0	0	0

D**No. at Risk**

Grade 1+2	31	19	11	7	5	1	1	0
Grade 3+4	14	8	7	3	1	0	0	0

12/41

Figure 8 contd.


E

Figure 9


A

Figure 9 contd.


B

Figure 9 contd.



C**CXCL10 vs CD8⁺ T cells****CXCL10 vs CD56⁺ T cells**

Figure 10




Figure 10 contd.



B**CXCL10****CCL5**

Figure 10 contd.


C

Figure 10 contd.


D

Figure 10D contd.




Figure 11




Figure 11 contd.


C**CCL2**

Figure 11 contd.



D

Figure 11 D contd.






Figure 11 contd.

E**CD3+ T cells**

SNU182		-	+	+	+
IFN- γ +poly(I:C)		-	+	+	+
PBMC	α -CXCR3	-	-	+	-
	α -CCR5	-	-	-	+

CD56+ NK cells

SNU182		-	+	+	+
IFN- γ +poly(I:C)		-	+	+	+
PBMC	α -CXCR3	-	-	+	-
	α -CCR5	-	-	-	+

Figure 12




Figure 12 contd.





Figure 12 contd.



C**CXCL10 vs Activated Caspase 3****D****TLR3 vs Activated Caspase 3**

Figure 12 contd.


E

Figure 12 contd.


F

Figure 13




Figure 14




Figure 15



A**Bootstrap_training cohort****Bootstrap_validation cohort**

Figure 15 contd.



B**Bootstrap_Stage I****Bootstrap_Stage II**

Figure 16




Figure 16 contd.







Figure 16 contd.



No. at Risk

Low	21	12	8	5	3	0	0	0
High	22	12	9	5	3	1	1	0



No. at Risk

Small	23	16	7	6	3	0	0	0
Big	20	10	10	3	3	1	1	0

Figure 17


A

Figure 17 contd..


B

Figure 17 contd.




Figure 18

